Creating a paradigm shift in renal care
Quanta Dialysis Technologies, today announces that the Company is unveiling its SC+ personal haemodialysis system for market launch next year. Based on clinical experience obtained during Quanta's extensive pilot studies, which included over 1,100 successful patient treatments at four NHS Trusts across the UK, the Company has optimised SC+ for commercial launch. In addition to the small, simple-to-use and powerful features that already set SC+ apart from traditional dialysis machines, Quanta is introducing state-of-the-art technology enhancements that include a new user interface featuring a high resolution screen and improved touch functionality, improvements for usability and capabilities to integrate with digital health solutions.
Quanta Dialysis Technologies, today announces that the Company will be exhibiting at the 10th UK Annual Dialysis Conference, taking place from Thursday 28th to Friday 29th September 2017, at the Lowry Hotel in Manchester, UK. The UK Annual Dialysis Conference theme for 2017 is 'Dialysis fit for the 21st century', which focuses on the challenges, improvements and outcomes faced by dialysis patients and clinicians in the UK. Patients, clinicians and researchers will explore and discuss topics of clinical interest, including effective integrated home dialysis models, clinical challenges in dialysis practice and quality improvement.
Quanta Dialysis Technologies, today announces that the Company will be attending the German Society of Nephrology 9th Annual Congress 2017 (DGFN 2017) taking place from Thursday 14th to Sunday 17th September 2017, at the Congress Center Rosengarten in Mannheim, Germany.
Quanta Dialysis Technologies, today announces that the Company will be exhibiting at the 54th European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress which runs from Saturday 3rd June to Tuesday 6th June at the IFEMA Conference Centre in Madrid, Spain at booth number 3.135. Quanta will be showcasing SC+, its easy-to-use, compact, haemodialysis system, offering high performance comparable to conventional devices and compatibility with traditional treatment regimens typically used in-centre. SC+ has been designed to provide flexibility and convenience to dialysis patients empowering them to regain control of their lives.
Quanta Dialysis Technologies is very excited to become part of the global kidney community as it approaches the 2018 commercial launch of its new haemodialysis system -the SC+. Over 64,000 people in the UK are currently being treated for end-stage renal disease and more than 24,000 undergo dialysis treatment to keep them alive. Quanta recognises that what most dialysis patients want is to be able to focus on their families, their work and their lives. Managing dialysis treatment can make that very challenging so there was clearly a need for a machine that is compact and easy to use, enabling greater flexibility and patient independence.
As I write this I am sitting in the desert outside Dubai, about to start a busy day of fun, jumping out of aeroplanes and horse riding in the sand dunes. The only reason I am here now, pursuing life with a passion and living very happily and healthily is because of home dialysis. 20 year's ago my life was turned upside down by an aggressive onset of FSGS. I spent 18 months in Guy's Hospital undergoing treatment including steroids and chemotherapy plus an array of horrible complications. At 14 years old I had my kidneys removed and immediately opted to dialyse myself at home on overnight APD.
Quanta Dialysis Technologies, today announces that the Company will be exhibiting at the British Renal Society Conference 2017, which runs from 26 to 28 April 2017, at the David Ross Sports Village, Nottingham University, UK. At the conference, Quanta will present a poster that will report on the results of the first 660 treatments completed using SC+ in the UK at Nottingham University Hospitals', Guys and St. Thomas' Hospital and Queen Elizabeth Hospital, Birmingham.
Quanta Dialysis Technologies, today announces that the Company will be presenting at the 37th Annual Dialysis Conference, which runs from 11 to 14 March 2017, at the Long Beach Convention and Entertainment Center in California, USA. John E. Milad, Chief Executive Officer will provide an update on Quanta's, easy-to-use, compact haemodialysis system, SC+, in the "Home Haemodialysis Machines: Providing Optimal Haemodialysis with Minimal Burdens" session chaired by Robert Lockridge, MD, on Sunday 12 March. John will also report on usability testing results for SC+ as part of the "Slide Forum VI: Dialysis Systems" session on Monday, 13 March.
The NIHR has supported Quanta Dialysis Technologies in the development of SC+, a high performance, compact, easy-to-use haemodialysis system designed to improve the lives of patients and carers both in the clinic and the home.
Quanta Dialysis Technologies, today announces it has appointed Dr Sandip Mitra to its Medical Advisory Board. Sandip is a practising Senior Consultant Nephrologist at Manchester Royal Infirmary where he leads one of the largest home haemodialysis programmes in Europe. He is a Principal Investigator on multicentre trials and is a recognised international advisor to global industry leaders in dialysis. Over the past 12 years he has held a number of research and clinical positions, including Renal Speciality Research Lead for the Clinical Research Network NIHR; Chair of Clinical Research Study Group for the UK Kidney Research Consortium NIHR; Renal Innovation Lead at MAHSC & Manchester Integrating Medicine & Innovative Technology (MIMIT); Clinical Chair, Renal Technology at NIHR Devices for Dignity; Senior Lecturer at the University of Manchester; and Clinical Governance Lead for the Hospital, Home and Minimal Care HD.